India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk

Dow Jones

2025/12/23

0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com)

(END) Dow Jones Newswires

December 23, 2025 01:10 ET (06:10 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2593616444"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593616444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593616444?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593616444","market":"sg","top_or_hot":-1,"title":"India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2025 01:10 ET (06:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia's GLP-1 Weight-Loss Drug Market Expected to Grow -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-23 14:10</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2025 01:10 ET (06:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4144","symbol_name":"石油與天然氣的儲存和運輸","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2593616444","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593616444","pubTimestamp":1766470200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp","BK4590":"PTP"},"translate_title":"印度GLP-1减肥药市场有望增长--市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"MNDmain":1.5},"content_text":"0610 GMT - India's market for GLP-1 weight-loss drugs is valued at several billion dollars and could grow to 4%-5% of the country's pharmaceutical market, Elarna Capital strategist Bino Pathiparampil says in a note. Semaglutide's sales volume is expected to surge as the GLP-1 drug goes generic in India next year, with the drug's wider use potentially adding 1%-2% to India's pharma sector growth, he says. Generic drugmakers with strong existing diabetes franchises are set to benefit the most, the strategist says, with Sun Pharmaceutical Industries, Lupin, Eris Lifesciences, Torrent Pharmaceuticals and Intas Pharmaceuticals best positioned. Dr. Reddy's and Zydus Life may also benefit, he adds. However, growth in GLP-1 treatments might cause other diabetes products to suffer, with the insulin market potentially shrinking by 10%-15%. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 01:10 ET (06:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}